Hemispherx treats first patient in clinical trial of Ampligen
Category: #health  By Nikita Chaurasia  Date: 2019-06-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Hemispherx treats first patient in clinical trial of Ampligen

Hemispherx Biopharma Inc., a US-based biopharmaceutical company recently announced having treated its first patient with Ampligen in combination with Cisplatin & Pembrolizumab, in a phase 2 ovarian cancer clinical trial.

As per credible sources, the study is evaluating Hemispherx' patented experimental drug Ampligen in combination with cisplatin and pembrolizumab, an anti-PD-1 check-point blockade therapy, under the leadership of principal investigator Robert Edwards. The study is expected to treat 45 patients. It is a second periodic ovarian cancer trial of Ampligen at University of Pittsburgh Medical Centre (UPMC).

For the record, Hemispherx Biopharma, Inc. is a pharmaceutical company, focused on R&D of therapeutics to treat multiple types of cancer. The company’s flagship product includes Ampligen and Alferon N Injection. Based on pre-clinical studies & clinical trials of Amligen, Hemispherx concluded the drug to have broad-spectrum anti-cancer & anti-viral properties. Already conducted clinical trials of Ampligen includes studies of potential treatment of cancer patients with malignant melanoma and renal cell carcinoma.

As per sources close to the matter, a phase 1/2 study was initiated approximately 3 years ago & is near completion of the phase 1 portion. The clinical outcome from initial phase 1/2 clinical trial of recurring ovarian cancer is being drafted by Dr. Edwards' team.

Dr. Edwards, chairman of gynecology services at UPMC’s Magee-Women's Hospital, Professor of Obstetrics, Gynecology & Reproductive Services at UPMC, was reported to say that the initial trial of Ampligen indicates that the drug is generally well-tolerated through intraperitoneal supervision and thus paved way for the new phase 2 study, combining Ampligen with pembrolizumab. Ampligen contains strong killer T-cell that can stay in tumor microenvironment without attracting regulatory T cells. The drug has the potential to be clinically significant by helping optimize barrier block induced tumor shrinkage.

Thomas K. Equels, CEO, Hemispherx, was reportedly quoted saying that Ovarian cancer is anticipated to kill 152,000 women this year world-wide. In the new study Hemispherx & the team at Magee-Women's Hospital of UPMC are focused on developing a life-saving therapy to meet this critical need.

Source credits: https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-First-Patient-Treated-in-Phase-2-Ovarian-Cancer-Clinical-Trial-Evalua

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Amazon Air to commence flights to Anchorage International Airport
Amazon Air to commence flights to Anchorage International Airport
By Nikita Chaurasia

Amazon Air recently announced that it plans to begin flights to Ted Stevens Anchorage International Airport. The airport published a post on twitter, confirming that the carrier will operate daily services to the Alaskan hub, utilizing its Boeing 767...

JetBlue to add long-range Airbus jets to expand services to Europe
JetBlue to add long-range Airbus jets to expand services to Europe
By Nikita Chaurasia

·         JetBlue, in April, had given confirmation of its first service to Europe starting 2021 ·         Its new Airbus jet would serve cities in north, ...

MobiKwik, DT One team up to offer mobile recharge services worldwide
MobiKwik, DT One team up to offer mobile recharge services worldwide
By Nikita Chaurasia

It will be the first time DT One will have mobile recharge originating from India through their network MobiKwik, an India based fintech platform, recently announced that it is partnering with DT One, a global network for mobile recharge and airtime...